Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EμMyc transgenic mice

Abstract

The basic helix–loop–helix factor E2A plays an important role in the development of B and T lymphocytes. In addition, E2a has been implicated as a gene with tumor suppressor activity, since mice deficient for E2a succumb to T cell lymphomas. We have performed retroviral tagging in EμMyc transgenic mice to identify genes that contribute to lymphomagenesis. The EμMyc transgenic mouse is a well-established model of a common translocation in human B cell lymphomas. Analyses of the proviral insertion sites in the MuLV-induced lymphomas revealed that a number of T cell lymphomas carried proviral insertions in the promoter region of E2a. These proviral insertions yield hybrid viral-E2a mRNAs resulting in a marked rise in E2A protein levels. The proviral insertions in E2a were predominantly of clonal origin indicating that E2a insertions are early events in these T cell lymphomas. The primary oncogenic effect of E2A is likely to be associated with enhancement of transcription of the c-Myc transgene via binding to the regulatory immunoglobulin enhancers. The results herein thus provide the first evidence that in a specific setting E2A overexpression can contribute to T-lymphomagenesis. This implies that E2a contains oncogenic features in addition to the previously described tumor suppressive properties.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL . 1985 Nature 318: 533–538

  • Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S . 1999 Oncogene 18: 5268–5277

  • Alexander WS, Schrader JW, Adams JM . 1987 Mol. Cell. Biol. 7: 1436–1444

  • Alkema MJ, van der Lugt NM, Bobeldijk RC, Berns A, van Lohuizen M . 1995 Nature 374: 724–727

  • Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A . 1997 Oncogene 15: 1133–1141

  • Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL, Chun J, Huey B, Pinkel D, Murre C . 1997 Mol. Cell. Biol. 17: 4782–4791

  • Bain G, Gruenwald S, Murre C . 1993 Mol. Cell. Biol. 13: 3522–3529

  • Bain G, Maandag EC, Izon DJ, Amsen D, Kruisbeek AM, Weintraub BC, Krop I, Schlissel MS, Feeney AJ, van Roon M . 1994 Cell 79: 885–892

  • Bain G, Quong MW, Soloff RS, Hedrick SM, Murre C . 1999 J. Exp. Med. 190: 1605–1616

  • Barndt RJ, Dai M, Zhuang Y . 2000 Mol. Cell. Biol. 20: 6677–6685

  • Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H . 1990 Cell 61: 49–59

  • Berns A, van der Lugt N, Alkema M, van Lohuizen M, Domen J, Acton D, Allen J, Laird PW, Jonkers J . 1994 Symp. Quant. Biol. 59: 435–447

  • Domen J, van der Lugt NM, Acton D, Laird PW, Linders K, Berns A . 1993 J. Exp. Med. 178: 1665–1673

  • Engel I, Johns C, Bain G, Rivera RR, Murre C . 2001 J. Exp. Med. 194: 733–745

  • Engel I, Murre C . 1999 Proc. Natl. Acad. Sci. USA 96: 996–1001

  • Felsher DW, Bishop JM . 1999 Mol. Cell 4: 199–207

  • Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE . 2001 Genes Dev. 15: 3249–3262

  • Gilks CB, Bear SE, Grimes HL, Tsichlis PN . 1993 Mol. Cell. Biol. 13: 1759–1768

  • Gorer PA . 1950 Br. J. Cancer 4: 372–379

  • Grimes HL, Gilks CB, Chan TO, Porter S, Tsichlis PN . 1996 Proc. Natl. Acad. Sci. USA 93: 14569–14573

  • Hsu B, Marin MC, el-Naggar AK, Stephens LC, Brisbay S, McDonnell TJ . 1995 Oncogene 11: 175–179

  • Inaba T, Roberts WM, Shapiro LH, Jolly KW, Raimondi SC, Smith SD, Look AT . 1992 Science 257: 531–534

  • Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M . 1999a Nature 397: 164–168

  • Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M . 1999b Genes Dev. 13: 2678–2690

  • Jonkers J, Berns A . 1996 Biochim. Biophys. Acta 1287: 29–57

  • Jonkers J, Korswagen HC, Acton D, Breuer M, Berns A . 1997 EMBO J. 16: 441–450

  • Kamps MP, Murre C, Sun XH, Baltimore D . 1990 Cell 60: 547–555

  • Kee BL, Murre C . 1998 J. Exp. Med. 188: 699–713

  • Kochetov AV, Ischenko IV, Vorobiev DG, Kel AE, Babenko VN, Kisselev LL, Kolchanov NA . 1998 FEBS Lett. 440: 351–355

  • Kuppers R, Dalla-Favera R . 2001 Oncogene 20: 5580–5594

  • Langdon WY, Harris AW, Cory S, Adams JM . 1986 Cell 47: 11–18

  • Mikkers H, Allen J, Knipscheer P, Romeyn L, Hart A, Vink E, Berns A . 2002 Nature Genet. (in press)

  • Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, Cabrera CV, Buskin JN, Hauschka SD, Lassar AB . 1989 Cell 58: 537–544

  • Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, Smith SD, Cleary ML . 1990 Cell 60: 535–545

  • Park ST, Nolan GP, Sun XH . 1999 J. Exp. Med. 189: 501–508

  • Peverali FA, Ramqvist T, Saffrich R, Pepperkok R, Barone MV, Philipson L . 1994 EMBO J. 13: 4291–4301

  • Rivera RR, Johns CP, Quan J, Johnson RS, Murre C . 2000 Immunity 12: 17–26

  • Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC . 1995 Oncogene 11: 2411–2418

  • Scheijen B, Jonkers J, Acton D, Berns A . 1997 J. Virol. 71: 9–16

  • Schlissel M, Voronova A, Baltimore D . 1991 Genes Dev. 5: 1367–1376

  • Shen CP, Kadesch T . 1995 Mol. Cell. Biol. 15: 4518–4524

  • van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH . 2002 Nature 415: 530–536

  • van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J, Berns A . 1995 EMBO J. 14: 2536–2544

  • van der Putten H, Terwindt E, Berns A, Jaenisch R . 1979 Cell 18: 109–116

  • van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A . 1989 Cell 56: 673–682

  • van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A . 1991 Cell 65: 737–752

  • Voronova AF, Adler HT, Sefton BM . 1987 Mol. Cell. Biol. 7: 4407–4413

  • Yan W, Young AZ, Soares VC, Kelley R, Benezra R, Zhuang Y . 1997 Mol. Cell. Biol. 17: 7317–7327

  • Zhao F, Vilardi A, Neely RJ, Choi JK . 2001 Mol. Cell. Biol. 21: 6346–6357

  • Zhuang Y, Soriano P, Weintraub H . 1994 Cell 79: 875–884

  • Zweidler-Mckay PA, Grimes HL, Flubacher MM, Tsichlis PN . 1996 Mol. Cell. Biol. 16: 4024–4034

Download references

Acknowledgements

We wish to thank C Murre for providing reagents, N Bosnie, L Rijswijk, A Zwerver, T Maidment, C Spaans and F van der Ahé for animal care, and M Nawijn for critically reading the manuscript. This work was supported by the Dutch Cancer Society (H Mikkers) and the Leukemia Society of America (J Allen).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anton Berns.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikkers, H., Allen, J. & Berns, A. Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EμMyc transgenic mice. Oncogene 21, 6559–6566 (2002). https://doi.org/10.1038/sj.onc.1205930

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205930

Keywords

This article is cited by

Search

Quick links